EUVIMEDEUVIMED entdecken
Crossref

Topical application of imatinib mesylate ameliorated psoriasis‐like skin lesions in imiquimod‐induced murine model via angiogenesis inhibition

Kazuma Hayakawa iD, Tatsuo Maeda, Chizu Egusa, Yukari Okubo iD, Kazutoshi Harada iD

Experimental Dermatology · 2023-06 · 32 (6) · 878-888

DOI: 10.1111/exd.14790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, online erschienen am 16.03.2023. Verfasst von Kazuma Hayakawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tokyo Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Psoriasis, Skin Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic skin disorder characterized by a skin rash with scaly patches. Microvascular abnormalities are a characteristic feature of psoriasis and play a crucial role in the pathogenesis of psoriatic lesions. Angiogenic factors are upregulated in psoriatic skin lesions and are thought to induce angiogenesis. Platelet‐derived growth factor (PDGF) induces vascular endothelial growth factor (VEGF), and PDGF is upregulated in keratinocytes in psoriatic skin lesions. The present study aimed to investigate the effect of topical imatinib mesylate (IMT) in inhibiting the activation of PDGF signalling in the pathogenesis of psoriasis. When topically applied to the skin of mice with imiquimod (IMQ)‐induced psoriasis, IMT ameliorated skin symptoms similar to those of human psoriasis. Hyperproliferation of keratinocytes, hyperkeratosis, inflammatory cell infiltration and hypervascularity were histologically suppressed by topical IMT. The expression of angiogenic factors including fibroblast growth factor (FGF) and VEGF was decreased. The expression of FGF and VEGF in a PDGF‐stimulated fibroblast cell line was inhibited by IMT. PDGF is required for the signalling pathway producing angiogenic factors in fibroblast. Thus, topically applied IMT inhibits PDGFR activation in fibroblast and suppresses the production of angiogenic factors, thereby mitigating the symptoms of psoriasis. The inhibitory effect of IMT on angiogenesis suggests that topical application IMT may be a viable treatment option for psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisSkin DiseasesHumansAnimalsMiceImiquimodImatinib MesylateVascular Endothelial Growth Factor ADisease Models, AnimalSkinKeratinocytesMice, Inbred BALB C

Stichwörter der Autor:innen

PDGFangiogenesisimatinib mesylateimiquimodpsoriasis

Substanzen

ImiquimodImatinib MesylateVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Dermatology, Tokyo Medical University, Tokyo, Japan.

ORCID-Profile: Kazuma Hayakawa, Yukari Okubo, Kazutoshi Harada

Zitieren

APA

Hayakawa, K., Maeda, T., Egusa, C., Okubo, Y., & Harada, K. (2023). Topical application of imatinib mesylate ameliorated psoriasis‐like skin lesions in imiquimod‐induced murine model via angiogenesis inhibition. Experimental Dermatology, 32(6), 878-888. https://doi.org/10.1111/exd.14790

Vancouver

Hayakawa K, Maeda T, Egusa C, Okubo Y, Harada K. Topical application of imatinib mesylate ameliorated psoriasis‐like skin lesions in imiquimod‐induced murine model via angiogenesis inhibition. Experimental Dermatology. 2023;32(6):878-888. doi:10.1111/exd.14790

BibTeX
@article{Hayakawa2023,
  author = {Hayakawa, Kazuma and Maeda, Tatsuo and Egusa, Chizu and Okubo, Yukari and Harada, Kazutoshi},
  title = {Topical application of imatinib mesylate ameliorated psoriasis‐like skin lesions in imiquimod‐induced murine model via angiogenesis inhibition},
  journal = {Experimental Dermatology},
  year = {2023},
  volume = {32},
  number = {6},
  pages = {878--888},
  doi = {10.1111/exd.14790}
}
Kostenlos starten →